Buchler T, et al. - Researchers analyzed 490 cases of metastatic colorectal cancer (mCRC)—181 treated with first-line epidermal growth factor receptor (EGFRi) plus second-line bevacizumab and 309 treated with first-line bevacizumab plus second-line EGFRi—to estimate the baseline ­characteristics and results of cases with mCRC and wild-type KRAS exon 2 status that were treated with ­bevacizumab and EGFRi (cetuximab or panitumumab). They observed similar median overall survival (OS) from the initiation of first-line therapy for cases treated with either sequence, ie, 31.8 vs 31.4 months for EGFRi → bevacizumab vs bevacizumab → EGFRi cohort, respectively, and time from the first-line initiation to succession on the second-line therapy was noted as 21.1 vs 19.3 months, implying no unusual differences in OS between cohorts.